Terns Pharmaceuticals, Inc. (TERN)

5.26 +0.18 (+3.44%) As of 12:06PM EDT. Market open.

Terns Pharmaceuticals, Inc.

1065 East Hillsdale Boulevard
Suite 100
Foster City, CA 94404
United States
650 525 5535
https://www.ternspharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 66

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Erin Quirk M.D.	President & Head of Research & Development	1.06M	N/A	1971
Dr. Mark Joseph Vignola Ph.D.	CFO & Treasurer	974.16k	N/A	1978
Mr. Seokho Yoon Esq.	COO, General Counsel & Secretary	921.05k	N/A	1978
Ms. Amy L. Burroughs M.B.A.	CEO & Director	N/A	N/A	1971
Dr. Jeffrey R. Jasper Ph.D.	Senior VP & Head of Research	N/A	N/A	N/A
Dr. Emil T. Kuriakose M.D.	Chief Medical Officer	N/A	N/A	1980
Ms. Melita Sun Jung	Chief Business Officer	N/A	N/A	1977

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Corporate Governance

Terns Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 29, 2024 is 7. The pillar scores are Audit: 8; Board: 7; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.